"The data we are presenting at IDWeek 2022 reinforce the positive safety and efficacy findings we previously described from our topline data analysis,” said
On
Oral Presentations
An oral presentation entitled Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections will be presented
The second oral presentation entitled Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections, will be presented
The third oral presentation titled Population pharmacokinetic (PPK), pharmacokinetic/pharmacodynamic attainment (PTA), and clinical pharmacokinetic/pharmacodynamic (PK/PD) analyses for sulbactam-durlobactam (SUL-DUR) to support dose selection for the treatment of Acinetobacter baumannii calcoaceticus complex (ABC) infections will be presented
Poster Presentations:
In addition to the oral presentations, three poster presentations highlighted additional SUL-DUR and ATTACK trial details and results.
Title: Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)
Summary: In the ATTACK trial, SUL-DUR achieved the primary safety objective of significantly reduced incidence of nephrotoxicity compared with colistin, was generally well tolerated in severely ill patients, and demonstrated a favorable safety profile with no new safety signals identified.
Presenter:
Poster #: 675
Date and time:
Title: Efficacy and safety of sulbactam-durlobactam (SUL-DUR) are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections
Summary: Results were consistently favorable for SUL-DUR vs colistin across regions for 28-day and 14-day all-cause mortality, clinical cure, microbiological favorable outcome, and nephrotoxicity based on RIFLE criteria.
Presenter: Khurram Rana, PharmD
Poster #: 225
Date and time:
Title: Characterization of colistin-resistant (COL-R) Acinetobacter baumannii-calcoaceticus complex (ABC) isolates from a recent global phase 3 trial (ATTACK)
Summary: A large number of
Presenter: Sarah McLeod, PhD
Poster #: 518
Date and time:
All Entasis IDWeek 2022 presentations will be made available on the Entasis website https://www.entasistx.com/our-science/presentations-by-event.
About Sulbactam-Durlobactam (SUL-DUR)
SUL-DUR is an intravenous, or IV, investigational drug that is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a novel broad-spectrum IV β-lactamase inhibitor, or BLI, being developed for the treatment of infections caused by Acinetobacter baumannii calcoaceticus complex (ABC), including carbapenem-resistant strains. Top-line results were announced in
SUL-DUR Expanded Access Program
About
Entasis is a late-stage clinical biopharmaceutical company, and wholly owned subsidiary of
About
ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GSK group of companies.
Cautionary Statement Regarding Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements regarding Innoviva’s completion of the offering, the anticipated principal amount of securities sold, the final terms of the offering, Innoviva’s anticipated use of proceeds, Innoviva’s ability to repurchase the 2023 Notes and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2022, which is on file with the SEC and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Innoviva’s other filings with the SEC, other unknown or unpredictable factors also could affect Innoviva’s results. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
Trademark reference: Innoviva and the Innoviva logo are registered trademarks or trademarks of Innoviva, Inc. or its affiliates in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners.
Company Contact
(781) 810-0114
kyle.dow@entasistx.com
Media Contact
(215) 315 3143
bwhelan@lifescicomms.com
Source:
2022 GlobeNewswire, Inc., source